Cancer Research The Future of Cancer Research: Science and Patient Impact AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Münster, P. N.
Right arrow Articles by Rosen, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Münster, P. N.
Right arrow Articles by Rosen, N.
[Cancer Research 61, 2945-2952, April 1, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

Inhibition of Heat Shock Protein 90 Function by Ansamycins Causes the Morphological and Functional Differentiation of Breast Cancer Cells1

Pamela N. Münster, Mary Srethapakdi, Mark M. Moasser and Neal Rosen2

Program in Cell Biology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

17-(Allylamino)-17-demethoxygeldanamycin (17-AAG) is an ansamycin antibiotic that binds to a conserved pocket in Hsp90 and induces the degradation of proteins that require this chaperone for conformational maturation. 17-AAG causes a retinoblastoma (RB)-dependent G1 block in cancer cells and is now in clinical trial. In breast cancer cells, G1 block is accompanied by differentiation and followed by apoptosis. The differentiation is characterized by specific changes in morphology and induction of milk fat proteins and lipid droplets. In cells lacking RB, neither G1 arrest nor differentiation occurs; instead, they undergo apoptosis in mitosis. Introduction of RB into these cells restores the differentiation response to 17-AAG. Inhibitors of the ras, mitogen-activated protein kinase, and phosphatidylinositol 3-kinase pathways cause accumulation of milk fat proteins and induction of lipid droplets when associated with G1 arrest but do not cause morphological changes. Thus, regulation of Hsp90 function by 17-AAG in breast cancer cells induces RB-dependent morphological and functional mammary differentiation. G1 arrest is sufficient for some but not all aspects of the phenotype. Induction of differentiation may be responsible for some of the antitumor effects of this drug.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
Y. Fukuyo, M. Inoue, T. Nakajima, R. Higashikubo, N. T. Horikoshi, C. Hunt, A. Usheva, M. L. Freeman, and N. Horikoshi
Oxidative Stress Plays a Critical Role in Inactivating Mutant BRAF by Geldanamycin Derivatives
Cancer Res., August 1, 2008; 68(15): 6324 - 6330.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Zajac, M. V. Moneo, A. Carnero, J. Benitez, and B. Martinez-Delgado
Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines
Mol. Cancer Ther., August 1, 2008; 7(8): 2358 - 2366.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. T. Chan, R. Paulmurugan, O. S. Gheysens, J. Kim, G. Chiosis, and S. S. Gambhir
Molecular Imaging of the Efficacy of Heat Shock Protein 90 Inhibitors in Living Subjects
Cancer Res., January 1, 2008; 68(1): 216 - 226.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. K. Francis, Y. Alsayed, X. Leleu, X. Jia, U. K. Singha, J. Anderson, M. Timm, H. Ngo, G. Lu, A. Huston, et al.
Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma.
Clin. Cancer Res., November 15, 2006; 12(22): 6826 - 6835.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. I. Robles, M. H. Wright, B. Gandhi, S. S. Feis, C. L. Hanigan, A. Wiestner, and L. Varticovski
Schedule-Dependent Synergy between the Heat Shock Protein 90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin and Doxorubicin Restores Apoptosis to p53-Mutant Lymphoma Cell Lines.
Clin. Cancer Res., November 1, 2006; 12(21): 6547 - 6556.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
W. Guo, P. Reigan, D. Siegel, J. Zirrolli, D. Gustafson, and D. Ross
The Bioreduction of a Series of Benzoquinone Ansamycins by NAD(P)H:Quinone Oxidoreductase 1 to More Potent Heat Shock Protein 90 Inhibitors, the Hydroquinone Ansamycins
Mol. Pharmacol., October 1, 2006; 70(4): 1194 - 1203.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Bauer, L. K. Yu, G. D. Demetri, and J. A. Fletcher
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
Cancer Res., September 15, 2006; 66(18): 9153 - 9161.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Martirosyan, S. Leonard, X. Shi, B. Griffith, P. Gannett, and J. Strobl
Actions of a Histone Deacetylase Inhibitor NSC3852 (5-Nitroso-8-quinolinol) Link Reactive Oxygen Species to Cell Differentiation and Apoptosis in MCF-7 Human Mammary Tumor Cells
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 546 - 552.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Glunde, V. Raman, N. Mori, and Z. M. Bhujwalla
RNA Interference-Mediated Choline Kinase Suppression in Breast Cancer Cells Induces Differentiation and Reduces Proliferation
Cancer Res., December 1, 2005; 65(23): 11034 - 11043.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
W. J. Lee, J. A. Robinson, N. A. Holman, M. N. McCall, S. J. Roberts-Thomson, and G. R. Monteith
Antisense-mediated Inhibition of the Plasma Membrane Calcium-ATPase Suppresses Proliferation of MCF-7 Cells
J. Biol. Chem., July 22, 2005; 280(29): 27076 - 27084.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. A. Mesa, D. Loegering, H. L. Powell, K. Flatten, S. J. H. Arlander, N. T. Dai, M. P. Heldebrant, B. T. Vroman, B. D. Smith, J. E. Karp, et al.
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
Blood, July 1, 2005; 106(1): 318 - 327.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. de Carcer
Heat Shock Protein 90 Regulates the Metaphase-Anaphase Transition in a Polo-Like Kinase-Dependent Manner
Cancer Res., August 1, 2004; 64(15): 5106 - 5112.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Umlauf, E. Csaszar, M. Moertelmaier, G. J. Schuetz, R. G. Parton, and R. Prohaska
Association of Stomatin with Lipid Bodies
J. Biol. Chem., May 28, 2004; 279(22): 23699 - 23709.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Zhang, W. Wu, Y. Du, S. J. Santos, S. E. Conrad, J. T. Watson, N. Grammatikakis, and K. A. Gallo
Hsp90/p50cdc37 Is Required for Mixed-lineage Kinase (MLK) 3 Signaling
J. Biol. Chem., May 7, 2004; 279(19): 19457 - 19463.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. P. Jansen, C. E. Camalier, C. Stark, and N. H. Colburn
Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity
Mol. Cancer Ther., February 1, 2004; 3(2): 103 - 110.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. J. H. Arlander, A. K. Eapen, B. T. Vroman, R. J. McDonald, D. O. Toft, and L. M. Karnitz
Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress
J. Biol. Chem., December 26, 2003; 278(52): 52572 - 52577.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. S. Bisht, C. M. Bradbury, D. Mattson, A. Kaushal, A. Sowers, S. Markovina, K. L. Ortiz, L. K. Sieck, J. S. Isaacs, M. W. Brechbiel, et al.
Geldanamycin and 17-Allylamino-17-demethoxygeldanamycin Potentiate the in Vitro and in Vivo Radiation Response of Cervical Tumor Cells via the Heat Shock Protein 90-Mediated Intracellular Signaling and Cytotoxicity
Cancer Res., December 15, 2003; 63(24): 8984 - 8995.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Enmon, W.-H. Yang, A. M. Ballangrud, D. B. Solit, G. Heller, N. Rosen, H. I. Scher, and G. Sgouros
Combination Treatment with 17-N-Allylamino-17-Demethoxy Geldanamycin and Acute Irradiation Produces Supra-Additive Growth Suppression in Human Prostate Carcinoma Spheroids
Cancer Res., December 1, 2003; 63(23): 8393 - 8399.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Poulaki, C. S. Mitsiades, C. McMullan, D. Sykoutri, G. Fanourakis, V. Kotoula, S. Tseleni-Balafouta, D. A. Koutras, and N. Mitsiades
Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5392 - 5398.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. de Candia, D. B. Solit, D. Giri, E. Brogi, P. M. Siegel, A. B. Olshen, W. J. Muller, N. Rosen, and R. Benezra
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors
PNAS, October 14, 2003; 100(21): 12337 - 12342.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Calabrese, A. Frank, K. Maclean, and R. Gilbertson
Medulloblastoma Sensitivity to 17-Allylamino-17-demethoxygeldanamycin Requires MEK/ERK
J. Biol. Chem., July 4, 2003; 278(27): 24951 - 24959.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. A. Vasilevskaya, T. V. Rakitina, and P. J. O'Dwyer
Geldanamycin and its 17-Allylamino-17-Demethoxy Analogue Antagonize the Action of Cisplatin in Human Colon Adenocarcinoma Cells: Differential Caspase Activation as a Basis for Interaction
Cancer Res., June 15, 2003; 63(12): 3241 - 3246.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. B. Solit, A. D. Basso, A. B. Olshen, H. I. Scher, and N. Rosen
Inhibition of Heat Shock Protein 90 Function Down-Regulates Akt Kinase and Sensitizes Tumors to Taxol
Cancer Res., May 1, 2003; 63(9): 2139 - 2144.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Villa, M. Folini, C. D. Porta, A. Valentini, M. Pennati, M. G. Daidone, and N. Zaffaroni
Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells
Carcinogenesis, May 1, 2003; 24(5): 851 - 859.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Chiosis, H. Huezo, N. Rosen, E. Mimnaugh, L. Whitesell, and L. Neckers
17AAG: Low Target Binding Affinity and Potent Cell Activity--Finding an Explanation
Mol. Cancer Ther., February 1, 2003; 2(2): 123 - 129.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Workman
Auditing the Pharmacological Accounts for Hsp90 Molecular Chaperone Inhibitors: Unfolding the Relationship between Pharmacokinetics and Pharmacodynamics
Mol. Cancer Ther., February 1, 2003; 2(2): 131 - 138.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Mitsiades, C. S. Mitsiades, V. Poulaki, D. Chauhan, G. Fanourakis, X. Gu, C. Bailey, M. Joseph, T. A. Libermann, S. P. Treon, et al.
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
PNAS, October 29, 2002; 99(22): 14374 - 14379.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. D. Basso, D. B. Solit, G. Chiosis, B. Giri, P. Tsichlis, and N. Rosen
Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function
J. Biol. Chem., October 11, 2002; 277(42): 39858 - 39866.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
V. Poulaki, C. S. Mitsiades, V. Kotoula, S. Tseleni-Balafouta, A. Ashkenazi, D. A. Koutras, and N. Mitsiades
Regulation of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Thyroid Carcinoma Cells
Am. J. Pathol., August 1, 2002; 161(2): 643 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman
Mechanisms of Action of Arsenic Trioxide
Cancer Res., July 15, 2002; 62(14): 3893 - 3903.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. N. Munster, D. C. Marchion, A. D. Basso, and N. Rosen
Degradation of HER2 by Ansamycins Induces Growth Arrest and Apoptosis in Cells with HER2 Overexpression via a HER3, Phosphatidylinositol 3'-Kinase-AKT-dependent Pathway
Cancer Res., June 1, 2002; 62(11): 3132 - 3137.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. B. Solit, F. F. Zheng, M. Drobnjak, P. N. Munster, B. Higgins, D. Verbel, G. Heller, W. Tong, C. Cordon-Cardo, D. B. Agus, et al.
17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/neu and Inhibits the Growth of Prostate Cancer Xenografts
Clin. Cancer Res., May 1, 2002; 8(5): 986 - 993.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
B Jones, E Aird, H Colyer, J Dobbs, R Harris, P Hoskin, A Mckenzie, and C West
United Kingdom Radiation Oncology 1 Conference (UKRO 1): Accuracy and uncertainty in radiotherapy
Br. J. Radiol., April 1, 2002; 75(892): 297 - 306.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
P. N. Munster, T. Troso-Sandoval, N. Rosen, R. Rifkind, P. A. Marks, and V. M. Richon
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells
Cancer Res., December 1, 2001; 61(23): 8492 - 8497.
[Abstract] [Full Text] [PDF]

Home page
 Cell Growth Differ.Home page
H. You, W. Yu, B. G. Sanders, and K. Kline
RRR-{alpha}-Tocopheryl Succinate Induces MDA-MB-435 and MCF-7 Human Breast Cancer Cells to Undergo Differentiation
Cell Growth Differ., September 1, 2001; 12(9): 471 - 480.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Sausville
Combining Cytotoxics and 17-Allylamino, 17-Demethoxygeldanamycin: Sequence and Tumor Biology Matters : Commentary re: P. Munster et al., Modulation of Hsp90 Function by Ansamycins Sensitizes Breast Cancer Cells to Chemotherapy-induced Apoptosis in an RB- and Schedule-dependent Manner. Clin. Cancer Res., 7: 2228-2236, 2001.
Clin. Cancer Res., August 1, 2001; 7(8): 2155 - 2158.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. N. Munster, A. Basso, D. Solit, L. Norton, and N. Rosen
Modulation of Hsp90 Function by Ansamycins Sensitizes Breast Cancer Cells to Chemotherapy-induced Apoptosis in an RB- and Schedule-dependent Manner : See The Biology Behind: E. A. Sausville, Combining Cytotoxics and 17-Allylamino, 17-Demethoxygeldanamycin: Sequence and Tumor Biology Matters. Clin. Cancer Res., 7: 2155-2158, 2001.
Clin. Cancer Res., August 1, 2001; 7(8): 2228 - 2236.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.